Harmen Beurmanjer

159 Supplements Population description and results Demographics: Total population: M=31.5, SD=10.1, median=29, range 18-67 years; 74% male, 23% female, 3% transgender; high school graduate or less (19%), some college (34%), bachelor degree or above (48%); not working (19%), attending school (12%), currently working (70%). U.S. respondents were older (p = 0.0003) and more highly educated (p < 0.001) compared to the non-U.S. respondents. Other: Total population: heterosexual (66%), gay/lesbian/bisexual (34%). GHB use: U.S. respondents: frequency of use: 1-2 (10%), 3-5 (16%), 6-20 (1%), <20 (72%); reason of use: body building (6%), being alone (20%), sexual (16%), dance/ clubs/ raves (20%), small private party (30%); quit using GHB > 6 months: yes (76%), no (24%); reason quitting: health/ safety (46%), legal (54%). Non-U.S. respondents: frequency of use: 1-2 (8%), 3-5 (9%), 6-20 (13%), <20 (69%); reason of use: body building (2%), being alone (17%), sexual (18%), dance/ clubs/ raves (29%), small private party (35%); quit using GHB > 6 months: yes (45%), no (55%); reason quitting: health/ safety (68%), legal (32%). Demographics: 60% male, M= 31 years, over 50% had completed college with 22% completing post- graduate or professional degrees, annual income >$60,000 (28%), 71% unmarried, significantly more female than male respondents were working (81% vs. 47%). Other: 61% heterosexual GHB use: first use M=27 (range 13-50) years; duration of M= 4 (range 1-11) years; 36% were light users (used GHB < 5 times in their lifetime), 41% were moderate users (6-50 times), and 24% were heavy users (> 50 times); 88% used GHB infrequently (< 1 day/week) mainly at parties and social gatherings. Other substance use: Large amount of the participants reported co-ingestion with other substance(s) at least once. Most commonly reported co-ingestion was with amphetamine, alcohol (43%), ecstasy, and marijuana. Demographics: 79% male; M=27, SD=6.7, range 17-50 years; 90% completed high school and 78% completed coursed following school; most participants were currently employed or were student (tertiary education); Other: 50% homosexual, 11% bisexual; small part (3%) of the population had a history of treatment for a drug use. GHB use: median length of use: 1 year; median occasions of use: 15; first use M=26, SD=6.7, range 16-49 years; median years of use: 1 (range 0-12); median times ever used GHB: 15 (range 1-2000); median days of GHB use past 6 months: 4 (range 0-180); GHB- dependent: 4%; 53% had experienced a GHB overdose. Participants who experienced GHB overdose had used it more times (life-time) and for a longer period of time. Other substance use: past 6 months: ecstasy (91%), amphetamine (77%), cocaine (83%), MDA (67%), methamphetamine (68%). Demographics: 90% male, M=26 years, 17% postsecondary education (non-GHB-users 21%), 12% >AU$ 60.000, 49% employed, 26% married. GHB use: first use M=24 years. Of the participants who ever used GHB, 76% did not use GHB in the past 12 months and 8% had used in the past month. A small part of the total population (0.5%) ever used GHB and a smaller population recently used GHB (0.1%). Lifetime GHB-use was highest amongst 20-29 years old. Other substance use: past year use of alcohol (99%), at least one occasion of >11 drinks in 1 day (49%), amphetamine (61%), cannabis (76%), heroin (9%), cocaine (32%), hallucinogens (24%), ecstasy (70%), ketamine (12%), inhalant use (13%). GHB users were more likely to report recent use of various other drugs than non-users.